Member Info for leeji

https://www.dailymail.co.uk/news/article-8780997/Multimillionaire-hedge-fund-manager-Crispin-Odey-61-pleads-not-guilty-groping-woman-1998.html

The Cancellation, Re-registration and adoption of the New Articles will require the approval of not less than 75 per cent. of the votes cast by Shareholders at the General Meeting. The Odey Entities, which between them hold 68,883,299 Ordinary Shares representing over 72% of the Company’s voting share capital have indicated to the Board that they intend to vote in favour of all the Resolutions. (9th Nov)
But then on 20th Nov had 69.83% 66,532,794

Finance
The Group is financed from the cash it generates from its operations, with the support of a bank overdraft facility of
£250,000 at a group level and £700,000 at an individual company level; the group also had a term loan however this
was repaid during the year. Post year end the group also entered a supplier financing facility of up to £500,000.
SO even in these poor times they managed to pay back the term loan of £71,558, maybe even benefited from furlong employee govt incomes.

A major Holder here is also connected to E-therapeutics (ETX), may be worth a little gamble.

Director shareholding

On 13 August 2020, Marc Boyan (via Miroma r4e Holdings Ltd), Chief Executive Officer, Director, and a PDMR, purchased 34,013,335 ordinary shares of 0.1p each in the Company at a price of 0.348p per Ordinary share. Following the purchase Mr Boyan holds 239,013,337 Ordinary shares representing approximately 18.73% of the total voting rights.

Freud increased to 18.67% on 12th

Net Assets Value and Gearing
The Group’s net assets at 31 December 2019 were USD92.0 million (2018: USD117.1 million). Net assets per share at 31 December 2019 were USD 0.24; GBP 0.18 (2018: USD0.31).
The Group’s cost of investment in Starry was USD 9.2 million under the equity accounting basis. Based on Starry’s closing price on 31 December 2019, the market value of the investment in Starry was approximately USD 40.9 million.
The difference between the book value and the market value of Starry was not included in the consolidated financial statements.
NAV not reflected in SP, or disposal, hoping for updates this week.

Should have had further updates by now, cash return is substantial.

Disposal of Starry Shares

Hong Kong, 23 July 2020 - Cathay International Holdings Limited (LSE: CTI.L) , an operator and investor in the growing healthcare sector in the People's Republic of China, announces that further to the approvals granted by Cathay's shareholders on 15 May 2020 and by the shareholders of its subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), on 13 July 2020, Lansen has further disposed on-market of an aggregate of 424,000 shares in Zheijang Starry Pharmaceutical Co., Ltd (Starry) at the price of RMB 78.10 per Starry Shares on 23 July 2020. The selling price of RMB 78.10 represented 6 per cent discount to the closing price of Starry Shares on the Shanghai Stock Exchange on 22 July 2020 .

The gross sale proceeds of disposal were approximately RMB33.11 million and, after deducting transaction costs and related tax, expected to be approximately RMB31.18 million (approximately US$4.46 million). Lansen is expected to recognise a net gain of approximately USD 3.96 million, of which USD 2.09 million is attributable to Cathay. The above-mentioned US$ amounts are converted based on the exchange rate of US$1=RMB6.9921, and the actual exchange rate used in conversion may be different.

As at the date of this announcement after the disposal of Starry Shares, 4,718,855 Shares are owned by the Lansen group (representing approximately 2.01% in Starry), which value will be subject to market price fluctuations.
Thats USD 22.58 receivable and another usd 25 soon.

Cathay International Holdings Limited
("Cathay" or the "Company")
TRANSFER OF LISTING
Hong Kong, 14 July 2020 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China , today announces that following the passing of a special resolution by its shareholders at the Company's general meeting held on 15 June 2020, the Company's listing category has been transferred from "premium listing (commercial company)" to "standard listing",
Seemed intent on keeping their listing.

Disposal of Starry Shares

Hong Kong, 22 July 2020 - Cathay International Holdings Limited (LSE: CTI.L) , an operator and investor in the growing healthcare sector in the People's Republic of China, announces that further to the approvals granted by Cathay's shareholders on 15 May 2020 and by the shareholders of its subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), on 13 July 2020, Lansen has further disposed on-market of an aggregate of 1,910,000 shares in Zheijang Starry Pharmaceutical Co., Ltd (Starry) at the price of RMB 73.75 per Starry Shares on 22 July 2020. The selling price of RMB 73.75 represented 3 per cent discount to the closing price of Starry Shares on the Shanghai Stock Exchange on 21 July 2020 .

The gross sale proceeds of disposal were approximately RMB140.86 million and, after deducting transaction costs and related tax, expected to be approximately RMB132.66 million (approximately US$19.03 million). Lansen is expected to recognise a net gain of approximately USD 16.8 million, of which USD 8.9 million is attributable to Cathay. The above-mentioned US$ amounts are converted based on the exchange rate of US$1=RMB6.9718, and the actual exchange rate used in conversion may be different.

As at the date of this announcement after the disposal of Starry Shares, 5,142,855 Shares are owned by the Lansen group (representing approximately 2.19% in Starry), which value will be subject to market price fluctuations.

Thats 20.49m to CTI so far, and more of the same to come. Selling slowly on hongkong market so as not to drop the price

Fri, 17th Jul 2020 12:12

RNS Number : 3779T
Cathay International Holdings Ld
17 July 2020

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

Cathay International Holdings Limited ("Cathay" or the "Company")

Disposal of Starry Shares

Hong Kong, 17 July 2020 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, announces that further to the approvals granted by Cathay's shareholders on 15 May 2020 and by the shareholders of its subsidiary, Lansen Pharmaceutical Holdings Limited (Lansen) (HKEX: 503), on 13 July 2020, Lansen has disposed on-market of an aggregate of 2,349,505 shares in Zheijang Starry Pharmaceutical Co., Ltd (Starry) at an average price of RMB 78.97 per Starry Shares during the period from 14 July 2020 up to 17 July 2020.

The gross sale proceeds of disposal were approximately RMB185.55 million and, after deducting transaction costs and related tax, expected to be approximately RMB174.68 million (approximately US$24.67 million). Lansen is expected to recognise a net gain of approximately USD 21.93 million, of which USD 11.59 million is attributable to Cathay. The above-mentioned US$ amounts are converted based on the exchange rate of US$1=RMB7.0795, and the actual exchange rate used in conversion may be different.

As at the date of this announcement after the disposal of Starry Shares, 7,052,855 Shares are owned by the Lansen group (representing 3% in Starry), which value will be subject to market price fluctuations.

The full text of the Lansen Announcement can be found at https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0717/2020071701148.pdf and will also be made available at the Announcements & Notices section of Lansen's homepage at http://holding.lansen.com.cn/en/newslist.aspx?NodeCode=10002000700050005.

- ENDS -

Cathay International Holdings Ld (CTI London Stock Exchange)
CTI London 51% holder.
LANSEN PHARMACEUTICAL HOLDINGS LIMITED
POSSIBLE VERY SUBSTANTIAL DISPOSAL: DISPOSAL OF LISTED SECURITIES OF ZHEJIANG STARRY PHARMACEUTICAL CO., LTD. AND NOTICE OF EXTRAORDINARY GENERAL MEETING
The Group’s audited book cost of investment in Starry of approximately RMB 64,020,000 as at 31 December 2019.
The audited net asset value of Starry as at 31 December 2019 and unaudited net asset value of Starry as at 31 March 2020 is approximately RMB 1,028,707,000 and RMB 1,079,275,000.
Nearly 20 fold return imminent on there investment.
DYOR